Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,977.00
Bid: 1,979.00
Ask: 1,981.00
Change: -22.00 (-1.10%)
Spread: 2.00 (0.101%)
Open: 1,991.00
High: 2,006.00
Low: 1,977.00
Prev. Close: 1,999.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 18th Jul 2014 07:55

Barclays: Credit Suisse cuts target price from 275p to 235p retaining a neutral rating.Barratt Developments: Liberum Capital reduces target price from 468p to 387p and downgrades to hold.Bellway: Liberum Capital reduces target price from 1900p to 1764p, while leaving its buy recommendation unchanged.Berkeley Group: Liberum Capital cuts target price from 2634p to 2613p retaining a hold recommendation.Bovis Homes Group: Liberum Capital reduces target price from 1034p to 930p and stays with its buy recommendation.Breedon: Jefferies shifts target price from 45p to 47p and reiterates a hold recommendation.British Land: Barclays raises target price from 695p to 936p, while its overweight rating remains unchanged.Burberry Group: Exane upgrades to outperform with a target price of 1700p.bwin.party: Deutsche Bank lowers target price from 110p to 100p and reiterates a hold recommendation.Croda International: Berenberg reduces target price from 2850p to 2700p, while keeping its buy recommendation.Drax Group: UBS moves target price from 790p to 800p and stays with its buy recommendation.GKN: Citi lowers target price from 435p to 410p, while staying with its buy recommendation.Gleeson: Liberum Capital cuts target price from 481p to 466p keeping a buy recommendation.Hays: Credit Suisse lowers target price from 165p to 150p and reiterates an outperform rating.Hikma Pharmaceuticals: Goldman Sachs raises target price from 1800p to 2250p and upgrades to buy.Hochschild Mining: Citi shifts target price from 110p to 116p, but still recommends selling.Howden Joinery: Berenberg initiates with a target price of 390p and a buy recommendation.Lloyds Banking Group: Citi lowers target price from 83p to 80p and retains a neutral rating.ISG: Jefferies shifts target price from 389p to 390p and keeps a buy recommendation.Michael Page: Credit Suisse cuts target price from 530p to 510p and maintains an outperform rating.Persimmon: Liberum Capital reduces target price from 1303p to 1238p and reiterates a hold recommendation.Reckitt Benckiser: Numis initiates with a target price of 5600p and an add rating.Redrow: Liberum Capital cuts target price from 320p to 307p and stays with its buy recommendation.Ricardo: Oriel raises target price to 700p and upgrades from reduce to buy.Robert Walters: Credit Suisse cuts target price from 380p to 360p and stays with its outperform rating.Standard Chartered: Deutsche Bank reduces target price from 1275p to 1160p and maintains a hold recommendation.SThree: Credit Suisse cuts target price from 450p to 420p and downgrades to neutral.Taylor Wimpey: Liberum Capital lowers target price from 132p to 130p maintaining a buy recommendation.Thorntons: Oriel initiates with a target price of 160p and a buy recommendation.William Hill: UBS cuts target price from 420p to 390p and retains a buy recommendation.
More News
21 Jun 2021 14:51

UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...

Read more
21 Jun 2021 14:31

U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents

WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...

Read more
8 Jun 2021 13:54

Tuesday broker round-up

(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.

Read more
6 May 2021 09:46

BROKER RATINGS: Exane BNP downgrades three property companies

BROKER RATINGS: Exane BNP downgrades three property companies

Read more
30 Apr 2021 17:01

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

LONDON MARKET CLOSE: Stocks close out impressive April to end higher

Read more
30 Apr 2021 08:58

TOP NEWS: Hikma Pharma confident after promising start to year

TOP NEWS: Hikma Pharma confident after promising start to year

Read more
30 Apr 2021 07:57

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

Read more
30 Apr 2021 07:38

Hikma predicts generics revenue at top of guidance

(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.

Read more
23 Apr 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
21 Apr 2021 12:08

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

Read more
21 Apr 2021 10:06

Hikma resumes asthma drug launch, Vectura pays special dividend

Hikma resumes asthma drug launch, Vectura pays special dividend

Read more
21 Apr 2021 09:01

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

Read more
21 Apr 2021 07:52

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

Read more
21 Apr 2021 07:30

Hikma resumes US launch of 'Advair Diskus' generic

(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.

Read more
19 Apr 2021 16:02

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.